Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

AustriaBack to Austria

Clinical trials in Graz – page 19

413 clinical trials in Graz, Austria across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Graz at a glance
413
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

413 trials in Graz

Open in trial search

Neurodermatitis

Not recruiting

Study on the Effects of Povorcitinib for Patients with Prurigo Nodularis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
  • Sponsor:Incyte Corp.

Non-small cell lung cancer

Not recruiting

Study of Durvalumab and Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Dermatitis atopic

Not recruiting

Study on the Long-Term Safety and Efficacy of Nemolizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nemolizumab
  • Sponsor:Galderma S.A.

Neurodermatitis

Not recruiting

Study on the Long-Term Safety and Effectiveness of Nemolizumab for Patients with Prurigo Nodularis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Nemolizumab
  • Sponsor:Galderma S.A.

Systemic scleroderma

Not recruiting

Study on the Effects of Fipaxalparant in Patients with Diffuse Cutaneous Systemic Sclerosis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Fipaxalparant
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Ovarian cancer

Not recruiting

Study on the Effectiveness of Durvalumab, Olaparib, and Bevacizumab in Patients with Newly Diagnosed Advanced Ovarian Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AstraZeneca AB

Eosinophilic oesophagitis

Not recruiting

Study on Long-Term Safety of Cendakimab for Adults and Adolescents with Eosinophilic Esophagitis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cendakimab
  • Sponsor:Celgene International II S.a.r.l.

Dermatitis atopic

Not recruiting

Study of Baricitinib for Children and Adolescents with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

Systemic scleroderma

Not recruiting

Study on the Effects of Fipaxalparant in Patients with Diffuse Cutaneous Systemic Sclerosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Fipaxalparant
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Arteriosclerosis

Not recruiting

Study of inclisiran to prevent heart attacks and strokes in people with atherosclerotic cardiovascular disease

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Novartis Pharma AG

Systemic scleroderma

Not recruiting

Study of anifrolumab effectiveness compared to placebo in adults aged 18-70 with systemic sclerosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Ischaemic stroke+2

Not recruiting

Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Asundexian
  • Sponsor:Bayer AG

Other cities in Austria

The busiest research cities in the country

All 47 cities in Austria

Clinical research in Graz

What the registry says about research in the country

01 Oncology Research

Innovative trials exploring treatments for various cancers, including bladder cancer, breast cancer, and gastric cancer. Studies focus on combination therapies and novel treatment approaches.

  • Early-stage bladder cancer treatment trials
  • HER2-positive cancer therapies
  • Pediatric liver cancer studies

Research emphasizes immunotherapy combinations and targeted treatments for better patient outcomes.

02 Metabolic Disorders

Clinical research focusing on diabetes management and obesity treatments. Studies include innovative approaches to blood glucose control and cardiovascular safety assessments.

  • Type 1 and Type 2 diabetes treatments
  • Obesity management therapies
  • Cardiovascular risk assessment

Investigations aim to improve treatment options and patient care strategies.

03 Inflammatory Conditions

Studies addressing various inflammatory diseases, including chronic rhinosinusitis and Crohn's disease. Research focuses on novel therapeutic approaches and disease management.

  • Nasal polyp treatments
  • Autoimmune disease therapies
  • Inflammatory response management

Trials evaluate both established and experimental treatment options.

Back to AustriaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.